Daly D C, Walters C A, Prior J C, Kuslis S T, Chapitis J, Andreoli J, Riddick D H
Am J Obstet Gynecol. 1984 Apr 15;148(8):1059-63. doi: 10.1016/s0002-9378(84)90445-9.
In vivo and in vitro endometrial stromal synthesis of prolactin occurs after progesterone-induced decidualization. Synthesis of prolactin by myometrium in vitro suggests that cells whose embryologic origin is the loose mesenchyme surrounding the paramesonephric ducts may retain the capacity to synthesize prolactin. Since physiologic myometrial synthesis of prolactin has not been demonstrated in vivo, prolactin genome expression in pathologic conditions was considered. Follicular phase leiomyomas were diced to 8 mm3 and cultured in Dulbecco's modified Eagle's medium (DMEM) with either no hormones, estradiol 200 pg/ml, progesterone 20 ng/ml, or estradiol and progesterone. Media were sampled and changed every other day for 8 days, followed by culture in tritium-labeled leucine DMEM for 2 days. Portions of leiomyomas were homogenized for initial prolactin content, and all samples were assayed for prolactin by radioimmunoassay. Follicular phase leiomyomas contained prolactin (47 +/- 15 ng/gm) in excess of normal serum values. Synthesis was demonstrated during all time periods from leiomyomas not exposed to progesterone. Progesterone variably suppressed the synthesis of prolactin until after 144 hours of culture. Determination of molecular weight on a 60 by 1.5 cm Sephadex G-100 column revealed identical estimates for pituitary, decidual, and leiomyoma prolactin. Tritium-labeled leucine incorporation into prolactin was confirmed by immunoprecipitation of Sephadex G-100 column fractions. Similar antigenicity was confirmed by parallel dilution curves for pituitary, decidual, and leiomyoma prolactin. Preliminary bioactivity in lymphoma proliferation assays confirmed prolactin activity. The conclusion reached was that proliferative phase leiomyomas contained elevated prolactin presumably secondary to in vivo synthesis. This synthesis was confirmed in vitro.
孕酮诱导蜕膜化后,子宫内膜基质在体内和体外均可合成催乳素。子宫肌层在体外合成催乳素表明,胚胎学起源于中肾旁管周围疏松间充质的细胞可能保留了合成催乳素的能力。由于尚未在体内证实子宫肌层有生理性催乳素合成,因此考虑了病理情况下催乳素基因组的表达。将卵泡期平滑肌瘤切成8立方毫米,在无激素、200皮克/毫升雌二醇、20纳克/毫升孕酮或雌二醇与孕酮的杜尔贝科改良伊格尔培养基(DMEM)中培养。每隔一天取样并更换培养基,持续8天,随后在氚标记亮氨酸的DMEM中培养2天。取部分平滑肌瘤匀浆测定初始催乳素含量,所有样品均采用放射免疫法测定催乳素。卵泡期平滑肌瘤所含催乳素(47±15纳克/克)超过正常血清值。未接触孕酮的平滑肌瘤在所有时间段均有合成表现。孕酮对催乳素合成的抑制作用各不相同,直至培养144小时后。在60×1.5厘米的葡聚糖G-100柱上测定分子量,结果显示垂体、蜕膜和平滑肌瘤催乳素的估计值相同。通过对葡聚糖G-100柱级分进行免疫沉淀,证实氚标记亮氨酸掺入了催乳素。垂体、蜕膜和平滑肌瘤催乳素的平行稀释曲线证实了相似的抗原性。淋巴瘤增殖试验中的初步生物活性证实了催乳素的活性。得出的结论是,增殖期平滑肌瘤中催乳素水平升高,可能继发于体内合成。体外实验证实了这种合成。